Interpace Biosciences, Inc. (IDXGD)
7.618
+0.37
(+5.08%)
USD |
OTCM |
Aug 28, 16:00
Interpace Biosciences EPS Diluted (Quarterly) : 0.0285 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0285 |
| March 31, 2026 | 0.1301 |
| December 31, 2025 | 4.089 |
| September 30, 2025 | 0.1644 |
| June 30, 2025 | -0.7235 |
| March 31, 2025 | 0.2972 |
| December 31, 2024 | 1.607 |
| September 30, 2024 | 1.895 |
| June 30, 2024 | 2.769 |
| March 31, 2024 | 0.8075 |
| December 31, 2023 | 1.226 |
| September 30, 2023 | -0.7108 |
| June 30, 2023 | 0.2027 |
| March 31, 2023 | 0.4074 |
| December 31, 2022 | -1.831 |
| September 30, 2022 | -16.75 |
| June 30, 2022 | -4.657 |
| March 31, 2022 | -2.670 |
| December 31, 2021 | -4.459 |
| September 30, 2021 | -4.275 |
| June 30, 2021 | -4.200 |
| March 31, 2021 | -5.144 |
| December 31, 2020 | -10.07 |
| September 30, 2020 | -7.719 |
| June 30, 2020 | -6.918 |
| Date | Value |
|---|---|
| March 31, 2020 | -11.90 |
| December 31, 2019 | -14.47 |
| September 30, 2019 | -98.44 |
| June 30, 2019 | -69.55 |
| March 31, 2019 | -4.864 |
| December 31, 2018 | -7.056 |
| September 30, 2018 | -5.390 |
| June 30, 2018 | -3.432 |
| March 31, 2018 | -5.732 |
| December 31, 2017 | -9.316 |
| September 30, 2017 | -7.527 |
| June 30, 2017 | -32.65 |
| March 31, 2017 | 27.50 |
| December 31, 2016 | 161.80 |
| September 30, 2016 | -206.27 |
| June 30, 2016 | -65.00 |
| March 31, 2016 | -135.00 |
| September 30, 2015 | -155.00 |
| June 30, 2015 | -230.00 |
| March 31, 2015 | -130.00 |
| December 31, 2014 | -250.00 |
| September 30, 2014 | -145.00 |
| June 30, 2014 | -90.00 |
| March 31, 2014 | -55.00 |
| December 31, 2013 | -125.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Exlites Holdings International, Inc. | -0.0002 |
| Xcelerate, Inc. | -0.0001 |
| Vivos Therapeutics, Inc. | -0.31 |
| Hinge Health, Inc. | 0.5167 |
| PD-Rx Pharmaceuticals, Inc. | -- |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 0.266M |
| Revenue (Quarterly) | 9.131M |
| Total Expenses (Quarterly) | 8.865M |
| Enterprise Value | 40.49M |
| Gross Profit Margin (Quarterly) | 61.91% |
| Profit Margin (Quarterly) | 2.91% |
| Earnings Yield | 57.91% |
| Operating Earnings Yield | 9.87% |
| Normalized Earnings Yield | 57.72 |